Navigation Links
Barr Receives Approval for Generic Taxol(R) Injection USP, 6mg/mL
Date:3/12/2008

s," "should," "intends," "estimates" and other words of similar meaning. Because such statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company's business. These factors include, among others: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non- infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies (including PLIVA d.d.) and products we acquire and implementing our new enterprise resource planning system; fluctuations in operating results, including the effects o
'/>"/>
SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... MA -- Trillions of bacteria live in each person,s ... help digest food and stave off harmful infections, but ... , To help shed light on the role of ... associate professor Eric Alm recently tracked fluctuations in the ... year. The findings, described in the July 25 issue ...
(Date:7/25/2014)... 25, 2014 The Conferee Networking committee ... for Conferee Networking. These two-hour sessions provide a unique ... and resolve problems, discuss new techniques, or brainstorm new ... submit a topic for consideration is August 31, 2014, ... The Conferee Networking committee will review the topics, and ...
(Date:7/25/2014)... -- Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... , today announced that it will release its unaudited financial ... market close on Thursday, August 14, 2014 EDT. The Company ... on Friday, August 15, 2014, at 8:00 a.m. EDT (Friday, ... review the Company,s financial results and provide an update on ...
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... biotechnology company in the emerging field of regenerative ... live webcast of a presentation to investors on ... 1:30 p.m. PDT.  The presentation will include an ... pipeline. To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
Breaking Biology Technology:Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... ) today announced that Dan Maher , Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare Conference in ... ... ... ...
... ... pressure switches and pressure transmitters moves to Hatfield, Pa. , ... Hatfield, PA (Vocus) March 17, 2010 -- ... a new production line for the recently acquired pressure gauge product family at its ...
... ... generation business intelligence software, today announced the availability of Centrifuge 1.8, the latest version ... ... Centrifuge Systems, Inc. , a leading provider of next generation business intelligence software, ...
Cached Biology Technology:BioMarin to Present at the Barclays Capital Global Healthcare Conference 2BioMarin to Present at the Barclays Capital Global Healthcare Conference 3Brooks Instrument Opens Pressure Gauge Production Line 2Brooks Instrument Opens Pressure Gauge Production Line 3Centrifuge Releases New Data Visualization Software 2Centrifuge Releases New Data Visualization Software 3
(Date:7/25/2014)... engineering at the University of Houston, has written ... organ development., "Introduction to Tissue Engineering: Applications and ... the field of artificial organ development. Metin Akay, ... UH, served as a series editor on the ... published books on the subject of growing artificial ...
(Date:7/25/2014)... of Adelaide has opened the way for the development of ... In Australia, annual barley production is second only to wheat ... of the most important diseases of barley. , Senior Research ... of special growths on the cell walls of barley plants ... , The research, by the ARC Centre of Excellence in ...
(Date:7/25/2014)... a complex congenital central nervous system disease that ... neural tubes during the embryonic phase. Many patients ... incontinence and neurocognitive retardation. Such problems decrease the ... Researchers at Ankara Physical Medicine and Rehabilitation Education ... in children with SB, using the Pediatric Evaluation ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2New hope for powdery mildew resistant barley 2
... formation of the centromere, a key cellular structure in powering ... earned him a paper in Nature Cell Biology ... year, for a maximum of five years. Lars Jansen ... in Portugal, last year to head the Epigenetic Mechanisms group. ...
... repairing DNA strands damaged by oxidation leads to several ... contributes to the development of cancer. That,s the conclusion ... by researchers at the National Institute of Standards and ... the New York University School of Medicine (NYUSM). ...
... CHICAGO The American Dietetic Association has released an ... diets, if well-planned, are healthful and nutritious for adults, ... treat chronic diseases including heart disease, cancer, obesity and ... of the Journal of the American Dietetic Association ...
Cached Biology News:Double success for Instituto Gulbenkian de Ciencia scientists working on chromosome segregation 2Genetically engineered mice yield clues to 'knocking out' cancer 2ADA releases updated position paper on vegetarian diets 2